Subscribe to RSS
DOI: 10.1055/s-0035-1559605
Prevalence of Retinopathy in Adult Patients with GCK-MODY and HNF1A-MODY
Publication History
received 11 February 2015
first decision 24 June 2015
accepted 15 July 2015
Publication Date:
04 August 2015 (online)
![](https://www.thieme-connect.de/media/eced/201509/lookinside/thumbnails/02-2015-0062-dia_10-1055-s-0035-1559605-1.jpg)
Abstract
We aimed to assess the prevalence of diabetic retinopathy (DR) in adult patients with GCK-MODY and HNF1A-MODY in Poland and to identify biochemical and clinical risk factors associated with its occurrence.
We examined 74 GCK mutation carriers, 51 with diabetes and 23 with prediabetes, respectively, and 63 patients with HNF1A-MODY. Retinal photographs, 12 for each patient, were done by a fundus camera. Signs of DR were graded according to the DR disease severity scale. Statistical tests were performed to assess differences between the groups and logistic regression was done for the association with DR.
The mean age at examination was 34.5±14.8 and 39.9±15.2 in the GCK-MODY and HNF1A-MODY groups, respectively. Mild nonproliferative DR (NPDR) was found in one patient with the GCK mutation and likely concomitant type 1 diabetes, whereas DR was diagnosed in 15 HNF1A-MODY patients: 9 with proliferative, 3 with moderate NPDR and 2 with mild NPDR. In univariate logistic regression analysis in the HNF1A-MODY group, significant results were found for diabetes duration, fasting glycemia, HbA1c, arterial hypertension, age at the examination, and eGFR. The strongest independent predictors of DR in HNF1A-MODY were markers of glucose control: HbA1c (OR: 2.05, CL%95: 1.2–3.83, p=0.01) and glucose (p=0.006, OR: 1.40, CL%95: 1.12–1.83) analyzed in 2 separated models. Additionally, arterial hypertension independently predicted DR (OR: 9.06, CL%95: 1.19–98.99, p=0.04) in the model with HbA1c as glycaemic control marker.
In conclusion, DR of any degree was not present in our GCK-MODY group, while in spite of young age almost every fourth subject with HNF1A-MODY showed signs of this complication.
-
References
- 1 Shields BM, Hicks S, Shepherd MH et al. Maturity-onset diabetes of the young (MODY): how many cases are we missing?. Diabetologia 2010; 53: 2504-2508
- 2 Malecki MT. The search for undiagnosed MODY patients: what is the next step?. Diabetologia 2010; 53: 2465-2467
- 3 McDonald TJ, Ellard S. Maturity onset diabetes of the young: identification and diagnosis. Ann Clin Biochem 2013; 50: 403-415
- 4 Ellard S, Bellanné-Chantelot C, Hattersley AT. European Molecular Genetics Quality Network (EMQN) MODY group Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabetes of the young. Diabetologia 2008; 51: 546-553
- 5 Steele AM, Shields BM, Shepherd M et al. Increased all-cause and cardiovascular mortality in monogenic diabetes as a result of mutations in the HNF1A gene. Diabet Med 2010; 27: 157-161
- 6 Pearson ER, Liddel WG, Shepherd M et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000; 17: 543-545
- 7 Matschinsky FM. Evolution of the glucokinase glucose sensor paradigm for pancreatic beta cells. Diabetologia 1993; 36: 1215-1217
- 8 Byrne MM, Sturis J, Clément K et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. J Clin Invest 1994; 93: 1120-1130
- 9 Stride A, Ellard S, Clark P et al. Beta-cell dysfunction, insulin sensitivity, and glycosuria precede diabetes in hepatocyte nuclear factor-1alpha mutation carriers. Diabetes Care 2005; 28: 1751-1756
- 10 Hattersley A, Bruining J, Shield J et al. The diagnosis and management of monogenic diabetes in children and adolescents. Pediatr Diabetes 2009; 12: 33-42
- 11 Velho G, Froguel P. Maturity-onset diabetes of the young (MODY), MODY genes and non-insulin-dependent diabetes mellitus. Diabetes Metab 1997; 23 (Suppl. 02) 34-37
- 12 Steele AM, Shields BM, Wensley KJ et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia. JAMA 2014; 311: 279-286
- 13 Grading diabetic retinopathy from stereoscopic color fundus photographs – an extension of the modified Airlie House classification . ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991; 98: 786-806
- 14 Skupien J, Gorczynska-Kosiorz S, Klupa T et al. Molecular background and clinical characteristics of HNF1A MODY in a Polish population. Diabetes Metab 2008; 34: 524-528
- 15 Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55: 622-627
- 16 Isomaa B, Henricsson M, Lehto M et al. Chronic diabetic complications in patients with MODY3 diabetes. Diabetologia 1998; 41: 467-473
- 17 Do DV, Wang X, Vedula SS et al. Blood pressure control for diabetic retinopathy. Cochrane Database Syst Rev 2015; 31 1: CD006127
- 18 American Diabetes Association. Standards of Medical Care in Diabetes 2015. Diabetes Care 2015; 38 (Supplement 1)